Insight to Pharmacokinetics of TKIs: Optimizing Practical Guidelines for Individualized Therapy

Objective: Tyrosine kinase inhibitors (TKIs) are widely used drugs which have high availability in reducing the activity of BCR-ABL1 tyrosine kinase, therefore they play an indispensable role in the treatment of Chronic myeloid leukemia (CML). Imatinib, dasatinib and nilotinib have been proved to have absolute bioavailability and stable blood concentration in humans. TKIs pharmacokinetics has close relationships with the clinical response and clinical treatment of CML. Keywords: Tyrosine kinase inhibitors (TKIs), chronic myeloid leukemia (CML), pharmacokinetics, influence factors, treatment, plasma concentration.